On the Cyberknife Dose Fraction of Liver Cancer Treatment
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 657
- Locations
- 1
- Primary Endpoint
- Local control rate
Study Overview
Brief Summary
The research aims to the primary hepatic carcinoma patients whose diameter of the single tumor is equal or less than 5cm.By supervising the changes of liver function, Child-Pugh score, ICG-R15 value, secondary reaction, incidence rate of RILD during and after the radiotherapy, meanwhile combining the outcome of the progression of disease and the condition of survival quality, the optimum proposal could be obtained and apply to clinic thus make the treatment safe, effective and personalized.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 30 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The participants are from 30 to 80 years of age, without gender restriction
- •With the hepatopathy background, the diagnosis of primary hepatic carcinoma is confirmed by image examination and laboratory test(the diagnosis criteria is according to the primary hepatic carcinoma rule of diagnosis and treat in 2007)
- •The max diameter of single tumor ≤5cm
- •Child-Pugh Classification(CPC) A or B
- •ECOG score 0 or 1
- •Leukocyte is more than 2×109/L and thrombocyte is more than 60×109/L
- •Kidney function is normal
- •Unsuitable or rejecting other therapies such as resection, liver transplantation etc
- •Anticipated lifetime is longer than six months
- •The participants who are voluntary comply with the requirements of research
- •The participants agree to sign the informed consent.
Exclusion Criteria
- •The metastasis occur outside of liver
- •Child-Pugh Classification(CPC)
- •The outline of tumor is not confirmed by image examination
- •With hepatic or any other abdomen radiotherapy history before
- •With severe internal medicine diseases
- •Bone marrow haematopoietic function or kidney function is severe failure
- •Intractable ascites
- •The position of tumor is nearby esophagus, stomach or intestine
- •The normal liver volume less than 700 cm3
Outcomes
Primary Outcomes
Local control rate
Time Frame: From date of the participants completing the therapy until the date of first documented progression, assessed up to 36 months.
Local control illustrates the time from the tumor appearance to progress (the diameter more than or equal to 1.5 times of original) .The ratio of the number of the local control patients to the whole number of patients is local control rate.
Overall survival rate
Time Frame: From date of the participants diagnosed until the date of death from any cause, assessed up to 36 months.
Overall survival rate means the ratio of the number of patients who are alive to the whole patients after the treatment.
Secondary Outcomes
- RILD rate(From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.)
- Child-Pugh score(From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.)
- the value of ICG R15(From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.)